Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to become due as well as an estimated $41M in non-cash stock compensation expense. Syndax (SNDX) expects that its cash, cash equivalents and marketable securities, together with the $350M from the sale of a portion of the Niktimvo royalty and anticipated product revenue and interest income, enables the company to reach profitability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax to present new data on revumenib in leukemia
- Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
- Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
- SNDX Upcoming Earnings Report: What to Expect?
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls